127 related articles for article (PubMed ID: 38698701)
41. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study.
Kaya E; Ozgok Y; Zor M; Eken A; Bedir S; Erdem O; Ebiloglu T; Ergin G
Adv Clin Exp Med; 2017 Oct; 26(7):1095-1099. PubMed ID: 29211357
[TBL] [Abstract][Full Text] [Related]
42. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically.
Lima CB; Angrimani DSR; Flores RB; Vannucchi CI
Domest Anim Endocrinol; 2021 Apr; 75():106601. PubMed ID: 33333452
[TBL] [Abstract][Full Text] [Related]
43. Perfusion change in benign prostatic hyperplasia before and after castration in a canine model: Contrast enhanced ultrasonography and CT perfusion study.
Yoon S; Alfajaro MM; Cho KO; Choi US; Je H; Jung J; Jang Y; Choi J
Theriogenology; 2020 Oct; 156():97-106. PubMed ID: 32682181
[TBL] [Abstract][Full Text] [Related]
44. Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation.
Jin BR; Kim HJ; Na JH; Lee WK; An HJ
J Adv Res; 2024 Mar; 57():135-147. PubMed ID: 37061215
[TBL] [Abstract][Full Text] [Related]
45. Canine Prostate Disease.
Christensen BW
Vet Clin North Am Small Anim Pract; 2018 Jul; 48(4):701-719. PubMed ID: 29933768
[TBL] [Abstract][Full Text] [Related]
46. Endogenous Zinc-Ion-Triggered In Situ Gelation Enables Zn Capture to Reprogram Benign Hyperplastic Prostate Microenvironment and Shrink Prostate.
Ge J; Fang C; Tan H; Zhan M; Gu M; Ni J; Yang G; Zhang H; Ni J; Zhang K; Xu B
Adv Mater; 2024 Mar; 36(11):e2307796. PubMed ID: 38096869
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of GDNF and FGF-1 in Canine Benign Prostatic Hyperplasia: Evidence for a Pathogenetic Role of Neural Growth Factor.
Khodamoradi P; Amniattalab A; Alizadeh S
J Comp Pathol; 2021 Jan; 182():43-53. PubMed ID: 33494907
[TBL] [Abstract][Full Text] [Related]
48. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Goswami K; Nandeesha H; Koner BC; Nandakumar DN
Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
[TBL] [Abstract][Full Text] [Related]
50. Power and pulsed Doppler evaluation of prostatic artery blood flow in normal and benign prostatic hyperplasia-affected dogs.
Zelli R; Orlandi R; Troisi A; Cardinali L; Polisca A
Reprod Domest Anim; 2013 Oct; 48(5):768-73. PubMed ID: 23505997
[TBL] [Abstract][Full Text] [Related]
51. High plasma estradiol-17beta levels in dogs with benign prostatic hyperplasia and azoospermia.
Kawakami E; Amemiya E; Namikawa K; Kashiwagi C; Hori T; Tsutsui T
J Vet Med Sci; 2001 Apr; 63(4):407-12. PubMed ID: 11346175
[TBL] [Abstract][Full Text] [Related]
52. Benign prostatic hyperplasia in the dog.
Cunto M; Ballotta G; Zambelli D
Anim Reprod Sci; 2022 Dec; 247():107096. PubMed ID: 36279818
[TBL] [Abstract][Full Text] [Related]
53. Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.
Moore RJ; Gazak JM; Quebbeman JF; Wilson JD
J Clin Invest; 1979 Oct; 64(4):1003-10. PubMed ID: 90055
[TBL] [Abstract][Full Text] [Related]
54. Expression of β-catenin and mesenchymal markers in canine prostatic hyperplasia and carcinoma.
Lean FZ; Kontos S; Palmieri C
J Comp Pathol; 2014 May; 150(4):373-81. PubMed ID: 24529514
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical expression of heat shock proteins, p63 and androgen receptor in benign prostatic hyperplasia and prostatic carcinoma in the dog.
Romanucci M; Frattone L; Ciccarelli A; Bongiovanni L; Malatesta D; Benazzi C; Brachelente C; Della Salda L
Vet Comp Oncol; 2016 Dec; 14(4):337-349. PubMed ID: 25059752
[TBL] [Abstract][Full Text] [Related]
56. An investigation on the relevance of prolactin, insulin-like growth factor-1 and 25-hydroxyvitamin D
Werhahn Beining F; Schmicke M; Wilkens M; Wolf K; Rohn K; Günzel-Apel AR
Vet Med Sci; 2021 Sep; 7(5):1493-1503. PubMed ID: 34015193
[TBL] [Abstract][Full Text] [Related]
57. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue.
Lin VK; Wang D; Lee IL; Vasquez D; Fagelson JE; McConnell JD
Prostate; 2000 Aug; 44(3):193-203. PubMed ID: 10906735
[TBL] [Abstract][Full Text] [Related]
58. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
Cohen SM; Taber KH; Malatesta PF; Shpungin J; Berman C; Carlin JR; Werrmann JG; Prahalada S; Bryan RN; Cordes EH
Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.
Hamakawa T; Sasaki S; Shibata Y; Imura M; Kubota Y; Kojima Y; Kohri K
Prostate; 2014 May; 74(6):590-601. PubMed ID: 24615654
[TBL] [Abstract][Full Text] [Related]
60. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
